BriaCell Therapeutics Corp. – Data Safety Monitoring Board Approval of Phase III Study

Summary of Regulatory Event

On 26 May 2026, BriaCell Therapeutics Corp. (TSX: BCT, Nasdaq: BCTX/BCTXL) announced that the independent Data Safety Monitoring Board (DSMB) for its pivotal Phase III study, Bria‑ABC (ClinicalTrials.gov identifier NCT06072612), issued its sixth consecutive positive recommendation. The DSMB reviewed the accumulated safety data for patients receiving Bria‑IMT™ in combination with a checkpoint‑inhibitor (CPI) for metastatic breast cancer and found no safety concerns. Consequently, the DSMB recommended that the study continue without modifications.

Study Overview

  • Investigational product: Bria‑IMT™, a whole‑cell vaccine developed by BriaCell’s proprietary BriaVax® technology.
  • Comparator: Standard checkpoint‑inhibitor therapy.
  • Population: Patients with metastatic breast cancer.
  • Study design: Randomized, controlled, Phase III, conducted under a Fast Track designation from the U.S. Food and Drug Administration (FDA), reflecting the significant unmet medical need in this disease area.

DSMB Findings

  • Safety profile: The DSMB identified no safety concerns to date.
  • Recommendation: Continue the study without any protocol modifications.
  • Frequency: DSMB meetings are held quarterly in accordance with the study protocol.

Regulatory Context

  • The Fast Track designation granted by the FDA accelerates the development and review process for therapies addressing unmet medical needs in metastatic breast cancer.
  • BriaCell’s Phase III program is a critical component of its strategy to bring its BriaVax® platform to market.

Company Commentary

“We are highly encouraged by the sixth consecutive positive recommendation of the DSMB for continuation of BriaCell’s pivotal Phase III Bria‑ABC study,” said Dr. William V. Williams, President and Chief Executive Officer of BriaCell.“This important milestone represents another step forward in advancing BriaCell’s novel immunotherapy approach.”

Market Implications

  • The announcement reinforces confidence in BriaCell’s clinical pipeline, potentially impacting investor perception of the company’s valuation.
  • BriaCell’s shares trade on the Toronto Stock Exchange under the ticker BCT; as of 26 May 2026, the closing price was 5.05 CAD.
  • The company’s market capitalization is approximately 35.96 million CAD, with a 52‑week range of 4.13 CAD to 49 CAD.

Conclusion

The DSMB’s sixth consecutive positive recommendation underscores the favorable safety and tolerability profile of BriaCell’s Bria‑ABC study. The continued progress of this Phase III program under Fast Track status positions BriaCell to address a significant unmet need in metastatic breast cancer, with potential implications for its future regulatory submissions and commercial prospects.